Abstract
Background Bladder cancer is one of the most prevalent malignancies worldwide. Despite its high incidence, public awareness of the condition remains low, and it has received less research attention compared to other common cancers. Over the past 80 years, patient outcomes and treatment strategies have remained largely unchanged, with cystoscopy being the primary method for detecting bladder cancer. This procedure, often repeated during long-term surveillance due to the recurrent nature of bladder tumors, is both uncomfortable for patients and costly for healthcare providers. The identification and validation of molecular biomarkers in blood, urine, or tissue could facilitate tumour detection and reduce reliance on cystoscopy.
Aim This study aims to identify potential molecular biomarkers for bladder cancer that could improve tumour detection and lessen the need for repeated cystoscopies.
Methods A systematic review was conducted, searching for articles related to bladder cancer biomarkers in four databases: PubMed, ScienceDirect, Google Scholar, and Cochrane. Studies that met the inclusion criteria underwent title/abstract screening and full-text review. A total of twenty studies were deemed eligible for inclusion in this review.
Results The review identified several gene product biomarkers, including TEAD4, TPM1, TPM2, SKA3, EO1, HYAL3, MTDH, EPDR1, hTERT, KRT7, SW, ARHGAP9, XPH4, OTX1, BUB1, and Usp28. Additionally, protein product biomarkers were identified, such as A1AT, APOE, AG, CA9, IL8, MMP9, MMP10, PAI1, SCDI1, SDC1, VEGFA, CD73, TIP2, CXCL5, PCAT6, and NCR3LG1 (B7-H6).
Conclusion The study highlights the potential of various gene and protein biomarkers for the detection of bladder cancer. Further research is necessary to validate these biomarkers’ diagnostic and prognostic potential in identifying bladder cancer in suspected cases.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
List of abbreviations
- (ATP)
- Adenosine triphosphate
- (BC)
- Bladder cancer
- (BTA)
- Bladder tumour antigen
- (CCD1)
- Cyclin D1
- (EMT)
- Epithelial to mesenchymal transition
- (IVU)
- Intrasonography intravascular urography
- (MIBC)
- Muscles invasive bladder cancer
- (NMIBC)
- Non-muscle invasive bladder cancer
- (MP22)
- Nuclear matrix protein 22
